John Edwards has 30 years of biopharmaceutical leadership experience which includes drug discovery, product development, commercialization, and business development. He has been involved in the development of over 10 FDA approved biologics and building five consecutive successful biotechnology companies. Along with ImmuneXcite, John is also Executive Chair of F-star. Previously, John helped lead Adnexus from a start-up to the $450M acquisition by BMS within 4 years, where he then continued with the company for the next 3 years serving as President. Prior to joining Adnexus, John was Vice President of Sales, Marketing, and Medical Affairs at Transkaryotic Therapies. Additionally, during his 15-year tenure with Genetics Institute/Wyeth, John held senior-level positions in R&D, manufacturing, and commercial operations, during which time he was responsible for building what has become a >$1B global pharmaceutical business in hematology. Following the acquisition of Genetics Institute by Wyeth he held senior-level positions in U.S. and global marketing at Wyeth, where he successfully launched 4 products in 3 different therapeutic areas (hematology, oncology, and immunology). John started his career at Genzyme (pre-IPO), working in R&D. John received his M.B.A. from Boston University and his B.S. in Chemical Engineering from the University of Massachusetts, Amherst.
Chief Scientific Officer and Acting CEO
Eric S. Furfine, Ph.D. joined ImmuneXcite as Chief Scientific Officer and acting-Chief Executive Officer in February 2016. Prior to ImmuneXcite, Eric spent 5 years at Eleven Biotherapeutics, where his roles included Chief Scientific Officer and President of Research and Development. Previous to Eleven Biotherapeutics, he served as the Senior Vice President of Research and Preclinical Development of Adnexus Therapeutics, Inc., a Bristol-Myers Squibb research and development company, from August 2006 to December 2010. Additionally, Eric served as the Vice President of Preclinical Development of Regeneron Pharmaceuticals, Inc., and in various senior level research positions at GlaxoSmithKline plc. Eric received an A.B. from Washington University in St. Louis and a Ph.D. in Biochemistry from Brandeis University.
EIR, Third Rock Ventures
Jim Geraghty was appointed a member of ImmuneXcite’s Board in November 2015. Currently an Entrepreneur-in-Residence at Third Rock Ventures and a founding director of Voyager Therapeutics, Jim is an industry leader with 30 years of strategic and leadership experience. Prior to Third Rock Jim served as Senior VP North America Strategy and Business Development at Sanofi, and spent 20 years at Genyzme, where he helped introduce rare disease therapies around the world. His roles included Senior VP, International Development; President of Genzyme Europe, where he oversaw several new product launches; and General Manager of Genzyme’s cardiovascular business, where he led strategic in-licensing transactions and guided the development of a now approved antisense product. He was previously Chairman, President, and CEO of Genzyme Transgenics Corporation (now Revo Biologics), which he founded and took public, and was earlier a manager at Bain & Company. Jim serves as Chairman of the Board of Idera Pharmaceuticals, a trustee of the Joslin Diabetes Center, and a director of BIO Ventures for Global Health. He holds a J.D. from the Yale Law School, an MS from the University of Pennsylvania and a BA from Georgetown University.
Eric Rowinsky, M.D.
Executive Director, RGenix Inc.
Dr. Rowinsky is the Executive Director, President, and Head of the Scientific Advisory Board at RGenix, a life sciences company focused on discovering new cancer targets using microRNA. He was the Head of R&D, Chief Medical Officer, and Executive Vice President of Stemline Therapeutics from 2012 to 2015. In 2010, Eric co-founded Primrose Therapeutics and became its CEO until it was acquired in 2011. From 2005 to December 2009, he served as the Chief Medical Officer and Executive Vice President of Clinical Development and Regulatory Affairs of ImClone Systems Incorporated, a life sciences company focused on monoclonal antibodies, and served on the company’s board of directors from 2005 to November 2008. Previously, Eric held several positions at the Cancer Therapy & Research Center’s Institute of Drug Development, including Director of the Institute and SBC Endowed Chair for Early Drug Development. Prior to that, he served as Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio and as Associate Professor of Oncology at the Johns Hopkins University School of Medicine. Eric is a member of the Board of Directors of Biogen Idec, a life sciences company. During the past five years, he has also served as a Director of BIND, Navidea, and Fortress Biosciences, all of which are public life sciences companies.
Managing Partner, Perspective Capital Management LLC
David is Managing Principal of Perspective Capital Management LLC a long/short hedge fund established in 1997. He began his career as a chemical engineer and then became a strategic planning consultant initially with The Boston Consulting Group and other firms later. In 1986, David entered the investment banking business as a stockbroker and analyst.
David is also active in the non-profit world through the Schechter Foundation. He serves on the Board of the JF&CS of Greater Boston, the New England Region Board of Facing History and Ourselves, the Board of MAB Community Services, the Board of Trustees of Beaver Country Day School, and the Board of Trustees of Beth Israel Deaconess Medical Center.
David graduated with honors from The University of Delaware with a Bachelor of Chemical Engineering and holds an MBA from the Wharton School at the University of Pennsylvania.
David and his wife, Gail, reside in Chestnut Hill with their two children, where he is the head of his neighborhood association.
Senior Director of Investments and Principal, Sanofi-Genzyme BioVentures
Ann joined Sanofi-Genzyme BioVentures in 2013 with a background in biotech partnering and early stage investment. Prior to SGBV, Ann was Senior Director, Corporate Development at Permeon Biologics, a Flagship Venture’s co-founded company. Previously, Ann was a Senior Associate at Flagship Ventures, an early stage venture capital firm investing in healthcare companies with $1.4 billion under management and was a Board observer for several portfolio companies including Taris Biomedical, Pervasis Therapeutics, and VisEn Medical. Post-doctorate, she worked at 3M Company in corporate research and in business units, including 3M Pharmaceuticals, and was a Technical Circle of Excellence Award winner.
Ann serves on the Board of ImmuneXcite and is a Board observer for Common Sensing. Ann serves on the Board of WEST, a non-profit organization dedicated to advancing women in the enterprise of science and technology. She is also a long-time member of the Life Sciences Council of Springboard Enterprises, an organization dedicated to building high-growth technology-oriented companies led by women.
Ann holds a B.S. from the University of Illinois in engineering, a Ph.D. from MIT in systems biology, and an M.B.A. from Harvard Business School.